AIM ImmunoTech Files 8-K: Agreements, Equity Sales, and Financials
Ticker: AIM · Form: 8-K · Filed: Oct 1, 2024 · CIK: 946644
Sentiment: neutral
Topics: material-agreement, equity-sale, financials
TL;DR
AIM ImmunoTech dropped an 8-K detailing new deals, stock sales, and financials. Check it out!
AI Summary
AIM ImmunoTech Inc. filed an 8-K on September 30, 2024, reporting on a material definitive agreement, unregistered sales of equity securities, and other events. The filing also includes financial statements and exhibits. The company, formerly known as Hemispherx Biopharma Inc., is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This 8-K filing provides crucial updates on AIM ImmunoTech's material agreements and equity transactions, offering insights into the company's financial activities and strategic developments.
Risk Assessment
Risk Level: medium — Filings related to material definitive agreements and unregistered sales of equity securities can indicate significant corporate actions that may impact stock price and investor confidence.
Key Numbers
- 001-27072 — SEC File Number (Identifies the company's filing history with the SEC.)
- 52-0845822 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- AIM ImmunoTech Inc. (company) — Registrant
- Hemispherx Biopharma Inc. (company) — Former company name
- September 30, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 2117 SW Highway 484, Ocala FL 34473 (address) — Principal executive offices
FAQ
What specific material definitive agreement was entered into by AIM ImmunoTech Inc. on or around September 30, 2024?
The filing indicates an 'Entry into a Material Definitive Agreement' as an item of disclosure, but the specific details of the agreement are not provided in this excerpt.
What was the nature of the unregistered sales of equity securities reported in this 8-K?
The filing lists 'Unregistered Sales of Equity Securities' as a reported event, but the specifics of the sale, including the amount and terms, are not detailed in this provided text.
When did AIM ImmunoTech Inc. change its name from Hemispherx Biopharma Inc.?
The date of the name change from Hemispherx Biopharma Inc. to AIM ImmunoTech Inc. was June 14, 1995.
What is the primary business of AIM ImmunoTech Inc. according to the SIC code?
AIM ImmunoTech Inc. is classified under SIC code 2836, which corresponds to 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)'.
Where are AIM ImmunoTech Inc.'s principal executive offices located?
The principal executive offices of AIM ImmunoTech Inc. are located at 2117 SW Highway 484, Ocala, FL 34473.
Filing Stats: 1,416 words · 6 min read · ~5 pages · Grade level 11.9 · Accepted 2024-10-01 15:55:19
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AIM NYSE American Item
- $0.28 — " C Warrants ") at an exercise price of $0.28 per share and Class D common warrants t
- $1.26 m — from the Transactions of approximately $1.26 million, before deducting fees to the Pla
Filing Documents
- form8-k.htm (8-K) — 55KB
- ex1-1.htm (EX-1.1) — 72KB
- ex4-1.htm (EX-4.1) — 111KB
- ex4-2.htm (EX-4.2) — 113KB
- ex5-1.htm (EX-5.1) — 16KB
- ex10-1.htm (EX-10.1) — 264KB
- ex99-1.htm (EX-99.1) — 12KB
- 0001493152-24-039011.txt ( ) — 951KB
- aim-20240930.xsd (EX-101.SCH) — 3KB
- aim-20240930_lab.xml (EX-101.LAB) — 33KB
- aim-20240930_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AIM ImmunoTech Inc. Date: October 1, 2024 By /s/ Thomas K. Equels Thomas K. Equels, CEO -4-